Transcutaneous Auricular Neurostimulation as a Treatment for Women With Heavy Menstrual Bleeding: A Dose-finding Trial

Description

This study is designed as an open label, single-arm, decentralized research study in which patients with idiopathic heavy menstrual bleeding will receive transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN). Participants will be enrolled over the course of three menstruations: one baseline menstruation and two menstruations with added daily neurostimulation.

Conditions

Heavy Menstrual Bleeding

Study Overview

Study Details

Study overview

This study is designed as an open label, single-arm, decentralized research study in which patients with idiopathic heavy menstrual bleeding will receive transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN). Participants will be enrolled over the course of three menstruations: one baseline menstruation and two menstruations with added daily neurostimulation.

Transcutaneous Auricular Neurostimulation as a Treatment for Women With Heavy Menstrual Bleeding: A Dose-finding Trial

Transcutaneous Auricular Neurostimulation as a Treatment for Women With Heavy Menstrual Bleeding: A Dose-finding Trial

Condition
Heavy Menstrual Bleeding
Intervention / Treatment

-

Contacts and Locations

Dallas

Five Liters - DECENTRALIZED STUDY, Dallas, Texas, United States, 75252

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Regularly menstruating female participants between 18-45 years of age
  • 2. History of menorrhagia as assessed by the Menorrhagia Screening Tool
  • 3. Stable/consistent use of current medications and supplements for the past three months, willingness to continue use for duration of study, and not start any new medications or homeopathic remedies
  • 4. Reliable access to an internet-enabled device to complete required questionnaires
  • 5. Willingness to consistently use the same brand of tampons and/or pads throughout duration of the study
  • 1. Pregnancy within three months of enrollment
  • 2. Lactating at the time of enrollment
  • 3. Typical length of menstruation greater than 14 days
  • 4. Use of hormone therapy in the past three months
  • 5. Antifibrinolytic use within 30 days of enrollment
  • 6. Known inherited or acquired bleeding disorder
  • 7. Use of anticoagulants (i.e., Aspirin, Warfarin, Coumadin, etc.) including platelet inhibitors for 30 days prior to enrollment
  • 8. Use of the Copper intrauterine device within the past 3 months
  • 9. Known structural cause of heavy menstrual bleeding
  • 10. Use of menstrual cups or menstrual underwear as a method of menstrual blood collection
  • 11. Participant has a history of chronic tobacco use or has ingested nicotine via smoking, vaping, smokeless tobacco, or nicotine patches in the past three months
  • 12. Participant has received a blood transfusion within 30 days prior to study
  • 13. Participant has a history of epileptic seizures
  • 14. Participant has a history of neurologic diseases or traumatic brain injury
  • 15. Participant has presence of devices (e.g., pacemakers, cochlear prostheses, neurostimulators)
  • 16. Participant has abnormal ear anatomy or ear infection present
  • 17. Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants are risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

Ages Eligible for Study

18 Years to 45 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Spark Biomedical, Inc.,

Study Record Dates

2025-06